Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report (ISRCTN no 36485475)

Rosser, Anne Elizabeth ORCID: https://orcid.org/0000-0002-4716-4753, Barker, Roger A., Harrower, T., Watts, C., Farrington, M., Ho, A. K., Burnstein, R. M., Menon, D. K., Gillard, J. H., Pickard, J. and Dunnett, Stephen Bruce ORCID: https://orcid.org/0000-0003-1826-1578 2002. Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report (ISRCTN no 36485475). Journal of neurology neurosurgery and psychiatry , pp. 678-685. 10.1136/JNNP.73.6.678

Full text not available from this repository.

Abstract

Objectives: Huntington’s disease (HD) is an inherited autosomal dominant condition in which there is a CAG repeat expansion in the huntingtin gene of 36 or more. Patients display progressive motor, cognitive, and behavioural deterioration associated with progressive cell loss and atrophy in the striatum. Currently there are no disease modifying treatments and current symptomatic treatments are only partially effective in the early to moderate stages. Neural transplantation is effective in animal models of HD and offers a potential strategy for brain repair in patients. The authors report a safety study of unilateral transplantation of human fetal striatal tissue into the striatum of four patients with HD. Subjects and methods: Stereotaxic placements of cell suspensions of human fetal ganglionic eminence were made unilaterally into the striatum of four patients with early to moderate HD. All patients received immunotherapy with cyclosporin A, azathioprine, and prednisolone for at least six months postoperatively. Patients were assessed for safety of the procedure using magnetic resonance imaging (MRI), regular recording of serum biochemistry and haematology to monitor immunotherapy, and clinical assessment according to the Core Assessment Protocol For Intrastriatal Transplantation in HD (CAPIT-HD). Results: During the six month post-transplantation period, the only adverse events related to the procedure were associated with the immunotherapy. MRI demonstrated tissue at the site of implantation, but there was no sign of tissue overgrowth. Furthermore, there was no evidence that the procedure accelerated the course of the disease. Conclusions: Unilateral transplantation of human fetal striatal tissue in patients with HD is safe and feasible. Assessment of efficacy will require longer follow up in a larger number of patients.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Biosciences MRC Centre for Neuropsychiatric Genetics and Genomics (CNGG) Neuroscience and Mental Health Research Institute (NMHRI)
Subjects:	R Medicine > R Medicine (General)
Uncontrolled Keywords:	Neural transplant ; Human fetal tissue ; Safety trial
Publisher:	BMJ Publishing Group
ISSN:	0022-3050
Last Modified:	17 Oct 2022 08:49
URI:	https://orca.cardiff.ac.uk/id/eprint/1140

Citation Data

Cited 155 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item